Meet with... National Cancer Institute
Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA
March 10, 2016 from 11:00 AM to 14:00 PM (PDT)
$10 - $35
This is a time of remarkable opportunity in cancer research. Armed with broad knowledge about how various kinds of cancers arise and with powerful new research tools, the research community, under the leadership of the National Cancer Institute (NCI), is poised to reduce the burden of cancer in this country and around the world at an accelerated pace.
NCI SBIR & STTR: FUNDING, MENTORING & NETWORKING ASSISTANCE FOR NEXT-GENERATION CANCER TECHNOLOGIES
The National Cancer Institute's SBIR Development Center program is one of the nation's largest sources of financing for technology innovation. Its funding, mentoring and networking assistance is offered to small businesses that demonstrate promising next-generation cancer cure technologies, with the ultimate goal being successful commercialization and life-changing public benefit. With initiatives such as the expanded I-Corps™ at NIH program, the NCI SBIR Development Center is powering innovation to enhance health, lengthen life, and reduce illness and disability.
Presenting at this event will be Xing-Jian Lou, Ph.D., Program Director, SBIR Development Center, National Cancer Institute. Dr. Lou will cover:
- Overview of SBIR/STTR eligibility requirements
- NIH SBIR/STTR process and new cancer-focused grant funding opportunities from NCI
- NCI SBIR/STTR initiatives such as the expanded I-Corps™ at NIH Program [guest speakers will share their insights about the I-Corps at NIH program]
- New NCI Investor Initiatives to help NCI SBIR-funded companies to connect with investors, venture capitalists, strategic partners, and business leaders from the biotech and pharmaceutical industries
- Practical strategies on how to successfully submit competitive research proposals
Following the presentation, selected companies will have the opportunity to meet one-on-one with directors. To be considered for a one-on-one meeting, please contact Christie Canaria, by Feb 25th with your name, company name, and a short executive summary.
10:00am | Registration Opens and Networking
10:30am | Presentation and Q&A [guest speakers will share their insights about the I-Corps at NIH program]
12:00pm | Networking Lunch
1:00-4:30pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. To be considered for a one-on-one meeting, please contact Christie Canaria, by Feb 25th with your name, company name, and a short executive summary.
Xing-Jian Lou | Program Director, SBIR Development Center, National Cancer Institute read bio»
David Charron | Educator and Thought Leader in Entrepreneurship and Innovation, UC Berkeley Haas School of Business read bio»
David Johnson | President and Chief Executive Officer, GigaGen, Inc. read bio»
National Cancer Institute Participating Representative:
Dr. Xing-Jian Lou | Program Director, SBIR Development Center, National Cancer Institute
Dr. Xing-Jian Lou is a Program Director in the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI). In this role, she actively engages in identifying areas of interest for NCI to develop Contract Topics and Funding Opportunity Announcements. She also conducts outreach events to help recruit more focused, commercially-minded SBIR applicants, and coaches small businesses to develop stronger applications and obtain government funding for innovative research and development projects with high commercial potential. Dr. Lou manages funded projects, mentoring and guiding companies throughout the award period, and facilitating their interaction with potential third-party investors and strategic partners. Dr. Lou has over 15 years experience in research and product development in the area of biomarker-, assay-, technology- and knowledgebase- development for diagnosis and drug development. Prior to joining NCI she held a variety of scientific and management positions in pharmaceutical and biotech companies, including Johnson & Johnson, LumiCyte, Applied Biosystems (now part of Thermo Fisher Scientific corporation) and diaDexus. Dr. Lou received her Ph.D. degree in Molecular & Cellular Pharmacology from the Miller Medical School of the University of Miami and completed her postdoctoral training at Stanford University
Connect with Xing-Jian:
About the National Cancer Institute:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
Connect with the NCI:
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until March 9th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time and be approved. To be considered for a one-on-one meeting, please contact Christie Canaria, by Feb 25th with your name, company name, and a short executive summary.
Guest Speakers Biographies:
David Charron | Educator and Thought Leader in Entrepreneurship and Innovation, University of California, Berkeley, Haas School of Business
David Charron is a member of the professional faculty at UC Berkeley where he teaches courses in innovation and entrepreneurship. He has been a core member of the leadership and teaching teams for the NSF and NIH I-Corps programs designed to train technology entrepreneurs customer-focused commercialization techniques. Mr. Charron has held leadership positions at Berkeley, run incubators, and worked in the field of technology commercialization and entrepreneurship for over 25 years at corporations such as Xerox PARC, academic institutions including MIT, Stanford, UC Berkeley and UCSF, and the national labs such as LBNL, LLNL and Sandia. He has also started several companies and actively advises new ventures.
Connect with David:
David Johnson, Ph.D. | President and Chief Executive Officer, GigaGen, Inc.
David Johnson, Ph.D., MBA, is an inventor, entrepreneur, and expert in experimental and computational genomics. During his graduate work in the Stanford University and afterward, his focus has been on applying innovative genomic technologies to important problems in basic and applied medical research. Dr. Johnson has spent significant time at the laboratory bench and also has developed customized bioinformatics software. He has led and organized several disparate and interdisciplinary research groups, including a major ENCODE effort for NHGRI and Natera's CLIA-regulated genomic diagnostics laboratory. At GigaGen, Dr. Johnson invented and then commercialized the world's first ultra-high throughput genomic system for generating synthetic immune systems from natural repertoires, financed mostly through industry partnerships and SBIR grants.
Connect with David:
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
Johnson & Johnson Innovation, JLABS
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California